Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen

Omeros logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Omeros from “Buy” to “Hold,” though the broader analyst consensus remains “Moderate Buy,” with an average price target of $30.33.
  • Omeros reported quarterly EPS of $0.06, beating the $0.02 estimate, while revenue of $35.93 million fell short of the $37.28 million forecast.
  • Company insiders sold a combined 75,906 shares over the past three months, worth about $1.44 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on OMER. Cantor Fitzgerald reissued an "overweight" rating and issued a $22.00 price target on shares of Omeros in a report on Wednesday, October 14th. Weiss Ratings raised shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $33.00 target price on shares of Omeros in a report on Tuesday. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Omeros has a consensus rating of "Moderate Buy" and an average price target of $30.33.

Check Out Our Latest Stock Report on Omeros

Omeros Stock Down 5.7%

Shares of Omeros stock opened at $13.21 on Friday. The firm has a market cap of $956.27 million, a price-to-earnings ratio of 13.76 and a beta of 2.96. The business has a fifty day simple moving average of $17.83 and a 200-day simple moving average of $13.80. Omeros has a fifty-two week low of $6.70 and a fifty-two week high of $21.24.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million for the quarter, compared to analyst estimates of $37.28 million. Analysts anticipate that Omeros will post -0.08 earnings per share for the current fiscal year.

Insider Activity at Omeros

In other news, Director Arnold Hanish sold 10,000 shares of the company's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the director directly owned 5,000 shares of the company's stock, valued at approximately $94,750. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Peter Cancelmo sold 25,000 shares of the business's stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares of the company's stock, valued at approximately $3,708. The trade was a 99.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 75,906 shares of company stock valued at $1,438,705. Corporate insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC boosted its position in Omeros by 75.3% during the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 758 shares during the period. Assetmark Inc. acquired a new position in Omeros during the first quarter valued at approximately $38,000. GK Wealth Management LLC bought a new position in shares of Omeros in the third quarter valued at approximately $65,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Omeros in the third quarter valued at approximately $70,000. Finally, Parallel Advisors LLC raised its position in shares of Omeros by 778.1% in the third quarter. Parallel Advisors LLC now owns 6,586 shares of the biopharmaceutical company's stock valued at $125,000 after purchasing an additional 5,836 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Key Omeros News

These are some of the OMER news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $33 price target, raising its FY2026 EPS estimate to a loss of $0.08 per share from a loss of $0.37, and increasing its FY2029 and FY2030 forecasts. Analyst forecasts for Omeros
  • Positive Sentiment: Cantor Fitzgerald reiterated a Buy rating, adding to the positive analyst commentary. Cantor Fitzgerald remains a Buy
  • Negative Sentiment: HC Wainwright trimmed its FY2028 EPS forecast to $1.56 from $1.63, a modest offset to its higher estimates for other years. Analyst forecasts for Omeros

Omeros Company Profile

(Get Free Report)

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Featured Stories

Analyst Recommendations for Omeros (NASDAQ:OMER)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines